Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Aclaris Therapeutics to Participate in Two February Healthcare Conferences
-
Aclaris Therapeutics’ Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA)
-
Aclaris Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with its Novel Bispecific Antibody ATI-052
-
Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052
-
Aclaris Therapeutics Added to the NASDAQ Biotechnology Index
-
Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
-
Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
-
Aclaris Therapeutics to Participate in Three November Healthcare Conferences
-
Aclaris Therapeutics to Host In-Person and Webcast R&D Day in New York on October 14, 2025
-
Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation at the 2025 European Academy of Dermatology and Ve